期刊论文详细信息
International Archives of Medicine
Virus against virus (VIVI): a potential solution against HIV/AIDS
Muhammad Muslim Noorani1  Muhammad Farhan Khaliq1  Asfandyar Sheikh1 
[1] Dow Medical College, Dow University of Health Sciences, Karachi, Pakistan
关键词: Vaccination;    HAART;    Super-infection;    Hepatitis G virus;    GBV-C;    AIDS;    HIV;   
Others  :  802414
DOI  :  10.1186/1755-7682-7-19
 received in 2013-05-18, accepted in 2014-04-11,  发布年份 2014
PDF
【 摘 要 】

Most therapeutic regimens are aimed at the use of pharmacologic agents or the induction of immunological response against the pathological agent. However, these methods tend to be insufficient for the management of some of the most debilitating infectious diseases. Here we present a novel therapeutic approach. It involves voluntary super-infection of a subject having HIV/AIDS with a virus (GBV-C), which to date has not been shown to be responsible for any pathology. It has been shown to counter, suppress or eradicate the agent responsible for the severe disease. Several studies demonstrate the role of different micro-organisms in influencing the growth of other pathogens in the human body. This hypothesis requires meticulous testing before its implementation on humans. If the trials are successful, the implications for this hypothesis are promising considering the compliance issues and adverse effects associated with current standard of HIV care.

【 授权许可】

   
2014 Sheikh et al.; licensee BioMed Central Ltd.

【 预 览 】
附件列表
Files Size Format View
20140708023617917.pdf 199KB PDF download
【 参考文献 】
  • [1]Xiang J, Wünschmann S, Diekema DJ, Klinzman D, Patrick KD, George SL, Stapleton JT: Effect of coinfection with GB virus C on survival among patients with HIV infection. N Engl J Med 2001, 345(10):707-714.
  • [2]Watt G, Kantipong P, Jongsakul K: Decrease in human immunodeficiency virus type 1 load during acute dengue fever. Clin Infect Dis 2003, 36(8):1067.
  • [3]Nunnari G, Nigro L, Palermo F, Attanasio M, Berger A, Doerr HW, Pomerantz RJ, Cacopardo B: Slower progression of HIV-1 infection in persons with GB virus C co-infection correlates with an intact T-helper 1 cytokine profile. Ann Intern Med 2003, 139(1):26-30.
  • [4]Lalle E, Sacchi A, Abbate I, Vitale A, Martini F, D’Offizi G, Antonucci G, Castilletti C, Poccia F, Capobianchi M: Activation of interferon response genes and of plasmacytoid dendritic cells in HIV-1 positive subjects with GB virus C co-infection. Int J Immunopathol Pharmacol 2008, 21(1):161.
  • [5]Leary TP, Muerhoff S, Simons JN, Pilot Matias TJ, Erker JC, Chalmers ML, Schalauder GG, Dawson GJ, Desai SM, Mushahwar IK: Sequence and genomic organization of GBV C: A novel member of the flaviviridae associated with human non A E hepatitis. J Med Virol 1996, 48(1):60-67.
  • [6]Stapleton JT: GB virus type C/hepatitis G virus. In 2003. New York: Thieme-Stratton, c1981; 2003:137-148.
  • [7]Alter MJ, Gallagher M, Morris TT, Moyer LA, Meeks EL, Krawczynski K, Kim JP, Margolis HS: Acute non-A–E hepatitis in the United States and the role of hepatitis G virus infection. N Engl J Med 1997, 336(11):741-746.
  • [8]Alter HJ, Nakatsuji Y, Melpolder J, Wages J, Wesley R, Shih JWK, Kim JP: The incidence of transfusion-associated hepatitis G virus infection and its relation to liver disease. N Engl J Med 1997, 336(11):747-754.
  • [9]Xiang J, McLinden JH, Rydze RA, Chang Q, Kaufman TM, Klinzman D, Stapleton JT: Viruses within the Flaviviridae decrease CD4 expression and inhibit HIV replication in human CD4+ cells. J Immunol 2009, 183(12):7860-7869.
  • [10]Ren FR, Wang Y, Li H, Chen HS, Zhao HY: Hepatitis G virus infection in screened Chinese blood donors. Vox Sang 1998, 74(1):51-52.
  • [11]Tanaka Y, Mizokami M, Orito E, Ohba K, Nakano T, Kato T, Kondo Y, Ding X, Ueda R, Sonoda S: GB virus C/hepatitis G virus infection among Colombian native Indians. Am J Trop Med Hyg 1998, 59(3):462-467.
  • [12]Bassit L, Kleter B, Ribeiro-dos-Santos G, Maertens G, Sabino E, Chamone D, Quint W, Saez-Alquezar A: Hepatitis G virus: prevalence and sequence analysis in blood donors of São Paulo, Brazil. Vox Sang 1998, 74(2):83-87.
  • [13]Dawson GJ, Schlauder GG, Pilot Matias TJ, Thiele D, Leary TP, Murphy P, Rosenblatt JE, Simons JN, Martinson FEA, Gutierrez RA: Prevalence studies of GB Virus C infection using reverse transcriptase polymerase chain reaction. J Med Virol 1996, 50(1):97-103.
  • [14]Hyland C, Mison L, Solomon N, Cockerill J, Wang L, Hunt J, Selvey L, Faoagali J, Cooksley W, Young I: Exposure to GB virus type C or hepatitis G virus in selected Australian adult and children populations. Transfusion 1998, 38(9):821-827.
  • [15]Masuko K, Mitsui T, Iwano K, Yamazaki C, Okuda K, Meguro T, Murayama N, Inoue T, Tsuda F, Okamoto H: Infection with hepatitis GB virus C in patients on maintenance hemodialysis. N Engl J Med 1996, 334(23):1485-1491.
  • [16]Thomas H, Pickering J, Karayiannis P: Identification, prevalence and aspects of molecular biology of hepatitis G virus. J Viral Hepat 1997, 4:51-54.
  • [17]Williams CF, Klinzman D, Yamashita TE, Xiang J, Polgreen PM, Rinaldo C, Liu C, Phair J, Margolick JB, Zdunek D: Persistent GB virus C infection and survival in HIV-infected men. N Engl J Med 2004, 350(10):981-990.
  • [18]Vahidnia F, Petersen M, Stapleton JT, Rutherford GW, Busch M, Custer B: Acquisition of GB virus type C and lower mortality in patients with advanced HIV disease. Clin Infect Dis 2012, 55(7):1012-1019.
  • [19]Xiang J, George SL, Wunschmann S, Chang Q, Klinzman D, Stapleton JT: Inhibition of HIV-1 replication by GB virus C infection through increases in RANTES, MIP-1alpha, MIP-1beta, and SDF-1. Lancet 2004, 363(9426):2040-2046.
  • [20]Supapol WB, Remis RS, Raboud J, Millson M, Tappero J, Kaul R, Kulkarni P, McConnell MS, Mock PA, Culnane M, McNicholl J, Roongpisuthipong A, Chotpitayasunondh T, Shaffer N, Butera S: Reduced mother-to-child transmission of HIV associated with infant but not maternal GB virus C infection. J Infect Dis 2008, 197(10):1369-1377.
  • [21]Giret MT, Kallas EG: GBV-C: state of the art and future prospects. Curr HIV/AIDS Rep 2012, 9(1):26-33.
  • [22]Schwarze-Zander C, Neibecker M, Othman S, Tural C, Clotet B, Blackard JT, Kupfer B, Luechters G, Chung RT, Rockstroh JK: GB Virus C (GBV-C) coinfection in advanced HIV disease is associated with low CCR5 and CXCR4 surface expression on CD4+ T cells. Antivir Ther 2010, 15(5):745.
  • [23]Nattermann J, Nischalke HD, Kupfer B, Rockstroh J, Hess L, Sauerbruch T, Spengler U: Regulation of CC chemokine receptor 5 in hepatitis G virus infection. AIDS 2003, 17(10):1457.
  • [24]Herrera E, Tenckhoff S, Gómara MJ, Galatola R, Bleda MJ, Gil C, Ercilla G, Gatell JM, Tillmann HL, Haro I: Effect of synthetic peptides belonging to E2 envelope protein of GB virus C on human immunodeficiency virus type 1 infection. J Med Chem 2010, 53(16):6054-6063.
  • [25]Björkman P, Flamholc L, Molnegren V, Marshall A, Güner N, Widell A: Enhanced and resumed GB virus C replication in HIV-1-infected individuals receiving HAART. AIDS 2007, 21(12):1641.
  • [26]Moss WJ, Ryon JJ, Monze M, Cutts F, Quinn TC, Griffin DE: Suppression of human immunodeficiency virus replication during acute measles. J Infect Dis 2002, 185(8):1035-1042.
  • [27]Williams A, Friedland G: Adherence, compliance, and HAART. AIDS Clin Care 1997, 9(7):51.
  • [28]Nischal K, Khopkar U, Saple D: Improving adherence to antiretroviral therapy. Indian J Dermatol Venereol Leprol 2005, 71(5):316.
  • [29]Spire B, Duran S, Souville M, Leport C, Raffi F, Moatti JP: Adherence to highly active antiretroviral therapies (HAART) in HIV-infected patients: from a predictive to a dynamic approach. Soc Sci Med 2002, 54(10):1481-1496.
  • [30]Ford N, Nachega JB, Engel ME, Mills EJ: Directly observed antiretroviral therapy: a systematic review and meta-analysis of randomised clinical trials. Lancet 2009, 374(9707):2064-2071.
  • [31]Bassetti S, Battegay M, Furrer H, Rickenbach M, Flepp M, Kaiser L, Telenti A, Vernazza PL, Bernasconi E, Sudre P: Why Is Highly Active Anti-retroviral Therapy (HAART) not prescribed or discontinued? J Acquir Immune Defic Syndr 1999, 21(2):114-119.
  • [32]Monforte AA, Lepri AC, Rezza G, Pezzotti P, Antinori A, Phillips AN, Angarano G, Colangeli V, Luca AD, Ippolito G, Caggese L, Soscia F, Filice G, Gritti F, Narciso P, Tirelli U, Moroni M: Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naive patients. AIDS 2000, 14(5):499-507.
  • [33]Anwer SMS, Ansari MH: Clouds with silver lining: Defining conditions that serve as blessings in disguise. El Mednifico Journal 2012, 1(1):19.
  文献评价指标  
  下载次数:5次 浏览次数:4次